Concepedia

Beth Ziegler

BZ

Statistics

Publications

3

Citations

186

H-Index

3

Active since

2010

Affiliations

Amgen (United States)(Current)

Beth Ziegler is an author at Amgen (United States) specializing in medicine, radiation oncology, and tumor biology.

Top concepts

Publications per year

2010–2015

3

Publications

3

Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines

Marc Payton, Tammy L. Bush, Grace Chung et al. · Cancer Research · 2010 · 118 citations · Full text

, , +18

Discovery of <i>N</i>-(4-(3-(2-Aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), A Highly Selective, Orally Bioavailable Inhibitor of Aurora Kinases with Activity against Multidrug-Resistant Cancer Cell Lines

Stephanie Geuns-Meyer, Victor J. Cee, Holly L. Deak et al. · Journal of Medicinal Chemistry · 2015 · 44 citations · Full text

, , +19

Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non–small-cell lung cancer xenograft models

Angela Coxon, Beth Ziegler, Stephen A. Kaufman et al. · Molecular Cancer · 2012 · 24 citations · Full text

1–3 of 3